Possible preventive effect of salazosulfapyridine against development of Pneumocystis pneumonia in methotrexate-receiving patients with rheumatoid arthritis

Kennosuke MizushinaDivision of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, Japan

Ayako HirataDivision of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, Japan

Norihide HayashiDivision of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, Japan

Sayaka TakenakaDivision of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, Japan

Hideki ItoDivision of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, Japan

Takehisa OguraDivision of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, Japan

Yuki FujisawaDivision of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, Japan

Munetsugu ImamuraDivision of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, Japan

Naoko YamashitaDivision of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, Japan

Rie KujimeDivision of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, Japan

Sumie NakahashiDivision of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, Japan

Hideto KamedaDivision of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, JapanCorrespondence[email protected] [email protected]

show all

Click to increase image sizeClick to decrease image size

Conflict of interest

H. Kameda has received research grants from AbbVie GK, Astellas Pharma, Chugai Pharmaceutical Co, Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co. Ltd., Santen Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd.; speaking fees from AbbVie GK, Astellas Pharma, Bristol–Myers K.K., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co. Ltd., Pfizer Japan Inc., Santen Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., and UCB Pharma; consultant fees from Eli Lilly Japan K.K., Novartis Pharma K.K. and Sanofi K.K.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Possible preventive effect of salazosulfapyridine against development of Pneumocystis pneumonia in methotrexate-receiving patients with rheumatoid arthritis

Information for

Open access

Opportunities

Help and information

Possible preventive effect of salazosulfapyridine against development of Pneumocystis pneumonia in methotrexate-receiving patients with rheumatoid arthritis

Conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature